BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$27.15-2.20%
Price as of Jul 20, 2026
BCAX financials
Bicara Therapeutics Inc. Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $155.6M | $82.4M | $39.9M | $37.7M |
| Operating income | -$155.6M | -$82.4M | -$39.9M | -$37.7M |
| Net income | -$137.9M | -$68.0M | -$52.0M | -$37.8M |
| EBITDA | -$137.6M | -$67.8M | -$52.0M | -$37.7M |
| Basic EPS | $-2.52 | $-1.25 | $-1.00 | $-0.73 |
| Diluted EPS | $-2.52 | $-1.25 | $-1.00 | $-0.73 |
| Balance sheet | ||||
| Cash & equivalents | $96.7M | $489.7M | $230.4M | $4.2M |
| Total assets | $431.0M | $569.2M | $234.0M | $6.7M |
| Total liabilities | $29.5M | $77.3M | $15.5M | $24.0M |
| Stockholders’ equity | $401.5M | $491.9M | $218.5M | -$17.3M |
| Total debt | $1.7M | $738.0K | $657.0K | $0.00 |
| Net debt | -$95.0M | -$489.0M | -$229.8M | -$4.2M |
| Cash flow | ||||
| Operating cash flow | -$106.8M | -$74.8M | -$45.6M | -$32.1M |
| Capital expenditure | -$280.0K | -$71.0K | -$586.0K | -$192.0K |
| Free cash flow | -$107.1M | -$74.8M | -$46.2M | -$32.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |